Abstract
Purpose. To evaluate the distribution of allometric exponents for relationship of total plasma clearance of 54 extensively metabolized drugs, with wide-ranging linear clearance values, between humans and rats, to provide a rationale for the observed data, and to discuss potential significance of the findings.
Methods. Human and rat plasma clearance values of 54 drugs with markedly different physicochemical properties were obtained from the literature. Standard allometric analysis was performed for each drug using both rat and human data. Unbound vs. total plasma clearances were obtained for 15 out of 54 drugs and their correlations between humans and rats were compared.
Results. The mean ± SD of the allometric exponent for the 54 drugs studied is 0.660 ± 0.190. The median clearance ratio based on unit body weight is 7.41 and the median exponent is 0.645. Excluding two outliers the correlation coefficient of plasma clearance between humans and rats was 0.745 (p < 0.0001). For the 15 drugs, use of unbound plasma clearance approach seems to significantly improve the correlation coefficient compared to total plasma clearance (0.940 vs. 0.841).
Conclusions. The present study indicates that on average, humans and rats may eliminate extensively metabolized drugs at a rate similar to that expected from the allometric or body surface area relationship of basal metabolic rate between the two species. A simple statistical distribution hypothesis is used to rationalize the species difference in plasma drug clearance. Rat may serve as an useful animal model to predict (unbound) plasma clearance of drugs in humans.
Similar content being viewed by others
REFERENCES
H. Boxenbaum. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokin. Biopharm. 8:165–176 (1980).
H. Boxenbaum. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokin. Biopharm. 10:201–227 (1982).
H. Boxenbaum and C. DiLea. First-Time-in-Human dose selection: Allometric thoughts and perpectives. J. Clin. Pharmacol. 35:957–966 (1995).
T. Lave, S. Dupin, C. Schmitt, R. C. Chou, D. Jaeck, and P. Coassolo. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J. Pharm. Sci. 86:584–590 (1997).
W. R. Chappell and J. Mordenti. Extrapolation of toxicological and pharmacological data from animals to humans. Adv. Drug Res. 20:1–116 (1991).
J. Mordenti, G. Gsaka, K. Garcia, K. Thomsen, V. Licko, and G. Meng. Toxicol. Appl. Pharmacol. 136:75–78 (1996).
M. Bonati, R. Latini, and G. Tognoni. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. Drug Met. Rev. 15:1355–1383 (1984–85).
Y. Sawada, M. Hanano, Y. Sugiyama, and T. Iga. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J. Pharmacokin. Biopharm. 13:447–492 (1985).
P. J. McNamara, in “Pharmaceutical Bioequivalence” ed. by P. G. Welling, F. L. S. Tse and S. V. Dighe, Marcel Dekker, Inc., New York, pp. 267–299, 1991.
D. B. Campbell. Can allometric interspecies scaling be used to predict human kinetics? Drug Inform. J. 28:235–245 (1994).
I. Mahmood and J. D. Balian. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895 (1996).
P. H. Hinderling, C. DiLea, T. Koziol, and G. Millington. Comparative kinetics of sematilide in four species. Drug Metab. Dispos. 21:662–669 (1993).
J. H. Lin. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23:1008–1021 (1995).
W. L. Chiou and F. H. Hsu. Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats. Pharm. Res. 5:668–672 (1988).
W. L. Chiou and Y. M. Choi. Unbound total (plasma) clearance approach in interspecies pharmacokinetics corelation: Theophyl-line-Cimetidine interaction. Pharm. Res. 8:1238–1239 (1995).
A. Hutchaleelaha, H. H. Chow, and M. M. Mayersohn. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J. Pharm. Pharmacol. 49:178–183 (1997).
J. E. Riviere, T. Martin-Jimenez, S. F. Sundlof, and A. L. Craigmill. Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. J. Vet. Pharmacol. Ther. 20:453–463 (1997).
F. E. Yates and P. N. Kugler. Similarity principles and intrinsic geometries: contrasting approaches to interspecies scaling. J. Pharm. Sci. 75:1019–1027 (1986).
Y. Sawada, M. Hanano, Y. Sugiyama, and T. Iga. Prediction of disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. J. Pharmacokin. Biopharm. 12:241–261 (1984).
J. M. Collins, C. K. Grieshaber, and B. A. Chabner. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Nat. Cancer Inst. 82:1321–1326 (1990).
W. S. Spector. Handbook of Biological Data, W. B. Saunder Co., Philadelphia, 1956.
L. Z. Benet, S. Øie, and J. B. Schwartz in “Goodman and Gilman's: The Pharmacological Basis of Therapeutics”, ed. by A. G. Gilman, J. G. Hardman, L. E. Limbard, P. B. Molinoff and R. W. Ruddon, 9th ed., McGraw Hill, New York, 1996.
J. H. Lin, M. Chiba, I. W. Chien, J. A. Nishime, and K. J. Vastag. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. Drug Metab. Dispos. 24:1298–1306 (1996).
J. M. Scavone, H. Friedman, D. J. Greenblatt, and R. I. Shader. Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. Arzneimittelforschung 37:2–6 (1987).
H. Matsushima, H. Kamimura, Y. Soeishi, T. Watanabe, S. Higuchi, and M. Tsunoo. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and in humans. Drug Metab. Dispos. 26:240–245 (1998).
A. R. Gascon, B. Calvo, R. M. Hernandez, A. Dominquez-Gill, and J. L. Pedraz. Interspecies scaling of theophylline-cimetidine pharmcokinetic interaction: interspecies scalling in pharmacokinetic interactions. Pharm. Res. 11:945–950 (1994).
P. Manitpisitkul and W. L. Chiou. Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. Biopharm. Drug Disposit. 14:555–566 (1993).
G. Levy, in “Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development” ed. by A. Yacobi, J. P. Skelly, V. P. Shah and L. Z. Benet. Plenum Press, New York, pp. 7–13, 1993.
W. L. Chiou. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics. Clin. Pharmacokinet. 17:175–199 (1989).
T. Lave, S. Dupin, M. Schmitt, M. Kapps, J. Meyer, B. Morgenroth, R. C. Chou, D. Jaeck, and P. Coassolo. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearances in animals and humans. Xenobiotica 26:839–851 (1996).
W. L. Chiou, A. Barve, G. Robbie, S. M. Chung, T. C. Wu, and C. Ma. New drug development: Are man and rat alike in pharmacokinetics and pharmacodynamics? Proceedings of the 14th International Conference on Advanced Science and Technology, Naperville, Illinois, pp 394–400, 1998.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chiou, W.L., Robbie, G., Chung, S.M. et al. Correlation of Plasma Clearance of 54 Extensively Metabolized Drugs Between Humans and Rats: Mean Allometric Coefficient of 0.66. Pharm Res 15, 1474–1479 (1998). https://doi.org/10.1023/A:1011974226596
Issue Date:
DOI: https://doi.org/10.1023/A:1011974226596